Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00379340 · ClinicalTrials.gov registry record · Phase 3

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

A Phase 3 study of Stage III Kidney Wilms Tumor and Stage IV Kidney Wilms Tumor, sponsored by Children's Oncology Group.

Active
Registry status
Phase 3
Development phase
395
Enrollment target
20
Study locations

NCT00379340: Active Phase 3 study of Stage III Kidney Wilms Tumor and Stage IV Kidney Wilms Tumor, sponsored by Children's Oncology Group.

NCT00379340 is a Phase 3 study of Stage III Kidney Wilms Tumor and Stage IV Kidney Wilms Tumor that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 395 participants, below the 438-participant average among 3 other Stage III Kidney Wilms Tumor trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00379340, a Phase 3 study of Stage III Kidney Wilms Tumor and Stage IV Kidney Wilms Tumor, is active but no longer recruiting, sponsored by Children's Oncology Group.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
395 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more tumor cells.

Primary Outcome

Probability of no relapse, secondary malignancy, or death after 4 year in the study.

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin Hydrochloride
  • PROCEDURE Conventional Surgery
  • BIOLOGICAL Dactinomycin
  • RADIATION 3-Dimensional Conformal Radiation Therapy

Study Locations (20)

California

  • Kaiser Permanente Downey Medical Center - Downey
  • Loma Linda University Medical Center - Loma Linda
  • Miller Children's and Women's Hospital Long Beach - Long Beach
  • Children's Hospital Los Angeles - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • Valley Children's Hospital - Madera
  • Children's Oncology Group - Oakland
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Kaiser Permanente-Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital Stanford University - Palo Alto
  • Sutter Medical Center Sacramento - Sacramento
  • University of California Davis Comprehensive Cancer Center - Sacramento

Alabama

  • Children's Hospital of Alabama - Birmingham
  • University of Alabama at Birmingham Cancer Center - Birmingham
  • USA Health Strada Patient Care Center - Mobile

Arizona

  • Phoenix Childrens Hospital - Phoenix
  • Banner University Medical Center - Tucson - Tucson

Arkansas

  • Arkansas Children's Hospital - Little Rock
  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 395 participants
Start Date 2007-04-30
Est. Completion 2026-11-18
Phase Phase 3
Children's Oncology Group

342 total trials

What the registry record for NCT00379340 still lists

NCT00379340 is an interventional study that assigns participants to a tested intervention. The registered 395 participants enrollment target is mid-sized for trials with a published cap, below the 438-participant average among 3 other Stage III Kidney Wilms Tumor trials with a reported enrollment target (10% lower).

The record links to 2 conditions, with Stage III Kidney Wilms Tumor appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT00379340 names 20 study sites across 4 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00379340 about?

NCT00379340 is a clinical study titled "Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor". This phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the ce...

What is the current status of trial NCT00379340?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 395 participants. The study started on 2007-04-30. Estimated completion is 2026-11-18.

What conditions does trial NCT00379340 study?

This clinical trial studies the following conditions: Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor.

What interventions are being tested in trial NCT00379340?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin Hydrochloride (DRUG), Conventional Surgery (PROCEDURE), Dactinomycin (BIOLOGICAL), 3-Dimensional Conformal Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT00379340?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00379340 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage III Kidney Wilms Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07207369 · 395 participants · Phase 3

    A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

  • NCT05633615 · 396 participants · Phase 2

    Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • NCT06227910 · 396 participants · Phase 3

    A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  • NCT06545331 · 396 participants · Phase 1

    Study of XB010 in Subjects With Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00379340, the US trial registry maintained by the National Library of Medicine. NCT00379340 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.